LSE:GSKPharmaceuticals
GSK’s Bepirovirsen Data And China Deal Reframe Hepatitis B Potential
GSK (LSE:GSK) and partners reported positive phase III data for bepirovirsen, a chronic hepatitis B therapy aiming for functional cure.
The global multi center trials showed meaningful functional cure rates and promising safety data in chronic hepatitis B patients.
GSK also announced a collaboration with Sino Biopharmaceutical’s Chia Tai Tianqing to accelerate bepirovirsen’s launch and commercialization in China.
For investors tracking LSE:GSK, this update sits at the crossroads of...